These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1440522)

  • 1. Pharmacological profile of a native dermatan sulfate.
    Santoro FM; Alvarez R; Fussi F
    Thromb Res; 1992 Jul; 67(2):201-11. PubMed ID: 1440522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulphate in rabbits.
    Saivin S; Caranobe C; Petitou M; Sie P; Lormeau JC; Level M; Crepon B; Houin G; Boneu B
    Br J Haematol; 1992 Apr; 80(4):509-13. PubMed ID: 1581235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model.
    Maggi A; Abbadini M; Pagella PG; Borowska A; Pangrazzi J; Donati MB
    Haemostasis; 1987; 17(6):329-35. PubMed ID: 3428718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
    Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
    Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
    Merton RE; Thomas DP
    Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the activity of a heparan sulphate of defined molecular weight range (7500-15,000 Da) with heparin and dermatan sulphate.
    Gervasi GB; Catalani R; Bartoli C; Carpita G; Farina C; Gelso E
    Pharmacol Res; 1995 Jun; 31(6):331-6. PubMed ID: 8685069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological actions of sulodexide.
    Ofosu FA
    Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin.
    Thomas DP; Gray E; Merton RE
    Thromb Haemost; 1990 Oct; 64(2):290-3. PubMed ID: 2270536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low affinity heparin is an antithrombotic agent.
    Gray E; Cesmeli S; Lormeau JC; Davies AB; Lane DA
    Thromb Haemost; 1994 Feb; 71(2):203-7. PubMed ID: 8191399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers.
    Tripodi A; Moia M; Bottasso B; Tenconi PM; Gianese F; Mannucci PM
    Thromb Res; 1991 Jun; 62(6):663-72. PubMed ID: 1926059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
    Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB
    Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and chronic effects of a new low molecular weight dermatan sulphate (Desmin 370) on blood coagulation and fibrinolysis in healthy subjects.
    Legnani C; Palareti G; Biagi R; Ludovici S; Maggiore L; Milani MR; Coccheri S
    Eur J Clin Pharmacol; 1994; 47(3):247-52. PubMed ID: 7867677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
    Hoppensteadt D; Walenga JM; Fareed J
    Thromb Res; 1990 Nov; 60(3):191-200. PubMed ID: 2084948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators.
    Castañon MM; Gamba C; Kordich LC
    Thromb Res; 2007; 120(5):745-52. PubMed ID: 17270255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats.
    Kitazato K; Kitazato KT; Nagase H; Minamiguchi K
    Thromb Res; 1996 Oct; 84(2):111-20. PubMed ID: 8897700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate.
    Fabiana Alberto M; Giaquinta Romero D; Lazzari M; Calabrese GC
    Thromb Res; 2008; 122(1):109-16. PubMed ID: 17936880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of dermatan sulphate reduces venous thrombus formation in vivo: potential use as a formulation for venous thromboembolism.
    Osborne SA; Masci PP; Du QS; Daniel RA; Desilva K; Vitetta L; Zhao KN; Seymour RB
    Inflammopharmacology; 2021 Apr; 29(2):525-535. PubMed ID: 33230702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
    Dol F; Petitou M; Lormeau JC; Choay J; Caranobe C; Sie P; Saivin S; Houin G; Boneu B
    J Lab Clin Med; 1990 Jan; 115(1):43-51. PubMed ID: 2299256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.